
- /
- Supported exchanges
- / US
- / RHHBF.OTCQX
Roche Holding AG (RHHBF OTCQX) stock market data APIs
Roche Holding AG Financial Data Overview
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Roche Holding AG data using free add-ons & libraries
Get Roche Holding AG Fundamental Data
Roche Holding AG Fundamental data includes:
- Net Revenue: 62 395 M
- EBITDA: 22 717 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-04-21
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Roche Holding AG News

Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)
Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena Corporation plc (NASDAQ:PRTA), has announced plans to initiate Phase 3 development...


AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study evaluated a combination therapy involving its blockbuster cancer drug Venclexta...

Genentech Provides Update on Phase III Verona Study
SOUTH SAN FRANCISCO, Calif., June 16, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and AbbVie announced today the outcome from the Phase III VERONA study...

AbbVie fails in late-stage trial for Roche-partnered blood cancer therapy venetoclax
[AbbVie headquarters building facade of an American publicly traded biopharmaceutical company] Michael Vi/iStock Editorial via Getty Images AbbVie (NYSE:ABBV [https://seekingalpha.com/symbol/ABBV]) a...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.